Interstitial lung disease (ILD) is one of the most serious pulmonary complications of connective tissue diseases (CTDs) and it is characterized by a deep impact on morbidity and mortality. Due to the poor knowledge of CTD-ILD's natural history and due to the difficulties related to design of randomized control trials, there is a lack of prospective data about the prevalence, follow-up, and therapeutic efficacy. For these reasons, the choice of therapy for CTD-ILD is currently very challenging and still largely based on experts' opinion. Treatment is often based on steroids and conventional immunosuppressive drugs, but the recent publication of the encouraging results of the INBUILD trial has highlighted a possible effective and safe use of antifibrotic drugs as a new therapeutic option for these subjects. Aim of this review is to summarize the available data and recent advances about therapeutic strategies for ILD in the context of various CTD, such as systemic sclerosis, idiopathic inflammatory myopathy and Sjogren syndrome, systemic lupus erythematosus, mixed connective tissue disease and undifferentiated connective tissue disease, and interstitial pneumonia with autoimmune features, focusing also on ongoing clinical trials.

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review / Vacchi, Caterina; Sebastiani, Marco; Cassone, Giulia; Cerri, Stefania; Della Casa, Giovanni; Salvarani, Carlo; Manfredi, Andreina. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:2(2020), pp. 407-407. [10.3390/jcm9020407]

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review

Vacchi, Caterina
Writing – Original Draft Preparation
;
Sebastiani, Marco
Writing – Review & Editing
;
Cassone, Giulia
Data Curation
;
Cerri, Stefania
Data Curation
;
Della Casa, Giovanni
Data Curation
;
Salvarani, Carlo
Supervision
;
Manfredi, Andreina
Writing – Review & Editing
2020-01-01

Abstract

Interstitial lung disease (ILD) is one of the most serious pulmonary complications of connective tissue diseases (CTDs) and it is characterized by a deep impact on morbidity and mortality. Due to the poor knowledge of CTD-ILD's natural history and due to the difficulties related to design of randomized control trials, there is a lack of prospective data about the prevalence, follow-up, and therapeutic efficacy. For these reasons, the choice of therapy for CTD-ILD is currently very challenging and still largely based on experts' opinion. Treatment is often based on steroids and conventional immunosuppressive drugs, but the recent publication of the encouraging results of the INBUILD trial has highlighted a possible effective and safe use of antifibrotic drugs as a new therapeutic option for these subjects. Aim of this review is to summarize the available data and recent advances about therapeutic strategies for ILD in the context of various CTD, such as systemic sclerosis, idiopathic inflammatory myopathy and Sjogren syndrome, systemic lupus erythematosus, mixed connective tissue disease and undifferentiated connective tissue disease, and interstitial pneumonia with autoimmune features, focusing also on ongoing clinical trials.
9
2
407
407
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review / Vacchi, Caterina; Sebastiani, Marco; Cassone, Giulia; Cerri, Stefania; Della Casa, Giovanni; Salvarani, Carlo; Manfredi, Andreina. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:2(2020), pp. 407-407. [10.3390/jcm9020407]
Vacchi, Caterina; Sebastiani, Marco; Cassone, Giulia; Cerri, Stefania; Della Casa, Giovanni; Salvarani, Carlo; Manfredi, Andreina
File in questo prodotto:
File Dimensione Formato  
Vacchi CTD ILD 2020.pdf

Open access

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 422.33 kB
Formato Adobe PDF
422.33 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1191846
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 21
social impact